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Abstract
Background: Diagnosis of HIV infection is recently occurring with increasing frequency in middle-
aged and in older individuals. As HAART became available, a minimal beneficial effect on
immunological outcome in older in respect of younger subjects has been reported. In fact, both the
intensity and the rapidity of the immunological response appeared to be reduced in elderly subjects.
On the contrary, only few reports have indicated a similar immunological outcome both in older
and younger HIV-positive subjects. Interestingly, older age did not seem to significantly affect the
long-term virological outcome of HAART treated subjects.
Methods:  To characterise epidemiological and clinical features of older HIV+ subjects, a
prospective case-control study was performed: 120 subjects ≥ 50 and 476 between 20 and 35 years
were initially compared. Subsequently, to better define the impact of HAART on their viro-
immunological response, 81 older were compared with 162 younger subjects.
Results: At baseline cases presented significantly lower TCD4+ cell number and were more
frequently affected by comorbid conditions. Under HAART a statistically significant increase in
TCD4+ cell number was observed in cases and controls. At multivariate analysis, there was no
statistically significant difference between cases and controls regarding viro-immunological
response.
Conclusions: Although older subjects present a more severe HIV infection, they can achieve,
under HAART, the same viro-immunological success as the younger individuals.
Background
Early in the epidemic, Human Immunodeficiency Virus
(HIV) infection primarily affected young adults; later on,
it occurred with increasing frequency in middle-aged and
in older individuals, too. In fact, a rate of 12.3% of AIDS
patients aged 50 years or older, with subjects ≥ 60 years
equalling 3.2%, has been recently reported by the Centres
for Diseases Control and Prevention (CDC) [1].
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Most of the known epidemiological features about older
HIV-infected subjects, have been defined before the intro-
duction of Highly Active Antiretroviral Therapy (HAART),
as the standard therapy for HIV-positive subjects, in 1996.
A low level of T CD4+ cells at HIV diagnosis [2,3], a rapid
decline of T CD4+ cell count [4,5] and a high level of HIV
viral load after seroconversion [6,7] have been reported in
older HIV-infected subjects. In addition, these individuals
presented a clinical condition of AIDS at the time of diag-
nosis of HIV infection more frequently than younger [2]
and they were more likely to die within one month after
HIV diagnosis [8]. Several studies have indicated that
older patients had a shorter survival than younger
[2,9,10], independently of HIV-risk behaviour [5,11,12]
and AIDS-related illnesses [13]. Either the more rapid
course [4,9] or the decreased survival [10,14] observed in
older subjects were considered to be determined by the
more frequent presence of non HIV-related comorbidities.
As HAART became available, a less beneficial effect on
immunological outcome in older in respect of younger
subjects has been reported [15-17]. In fact, both the inten-
sity [15,16] and the rapidity [17] of the immunological
response appeared to be reduced in older subjects. On the
contrary, only few reports have indicated a similar immu-
nological outcome both in older and younger HIV-posi-
tive subjects [18,19]. Interestingly, older age did not seem
to significantly affect the long-term virological outcome of
HAART treated subjects [15,18,20].
Two were the aims of this study:
1. To characterise the epidemiological and clinical fea-
tures of older subjects at the time of HIV diagnosis in the
HAART era.
2. To better define the impact of HAART on virological
and immunological response in a cohort of older HIV-
positive patients when confounding variables such as
adherence to therapy, side effects and non HIV-related
comorbidities were evaluated.
Methods
Study setting
The Catholic University teaching hospital is a 1,900-bed
tertiary care centre located in Rome, Italy, with approxi-
mately 67,000 patient admissions each year. There is a 60-
bed unit for the admission of HIV-infected subjects and a
day-hospital for out-patient care.
Study design
Prospective case-control study.
Study population
All patients presenting the first HIV positive test from Jan-
uary 1997 to June 2003, admitted to our in- and out-
patient care, were considered.
For the first aim of the study, subjects aged ≥ 50 years
(older) and between 20 and 35 years (younger) were
identified.
For the second aim of the study, older and younger
patients who were given HAART regularly and with a fol-
low-up of at least six months, were included as cases and
controls, respectively (ratio 1:2). The control group was
matched by sex, year of HIV diagnosis, presence of AIDS
defining conditions and type of HAART regimen (i.e.
NNRTI containing vs. PI containing regimens). A patient
(either case or control) was considered as regularly
HAART-treated if he/she was under antiretroviral therapy
with a combination of two nucleoside reverse tran-
scriptase inhibitors (NRTI) plus either a non nucleoside
reverse transcriptase inhibitor (NNRTI) or a protease
inhibitor (PI), as single drug or with the addiction of a low
dose of ritonavir (i.e. 100 mg bid), for at least three
months.
Parameters evaluated
Patients' records were reviewed by one of us, using a
standardised data collection form with predefined criteria.
For each subject enrolled in the study, the following data
were obtained at inclusion after patient's informed con-
sent: age, gender, HIV-risk behaviour, date of the first
available HIV test, reason for HIV testing, CDC stage of
HIV infection [21], HIV-related conditions, date of AIDS
diagnosis, number of hospitalisations after HIV diagnosis,
observed AIDS free interval (i.e. time from HIV infection
to AIDS diagnosis), type and use of prophylaxis for Pneu-
mocystis carinii pneumonia (PCP) and toxoplasmosis,
antiretroviral therapy (type, duration, adherence and side
effects) and other medications (antituberculous drugs,
antivirals, corticosteroids, antacids), time of follow-up,
time from AIDS diagnosis to death, cause of death.
Data collected from the laboratory records included:
numbers of circulating CD4+ T cells (/mm3), CD8+ T cells
(/mm3) and plasma HIV RNA viral load (copies/ml) with
a limit of detection below 50 copies/ml. The time of the
beginning of HAART was considered as time zero in the
analysis. All subjects underwent periodical clinical evalu-
ations including determination of CD4+ T cells and HIV
viral load every six months.
Adherence was defined through a self-reported evaluation
by the patient and registered as percentage by the physi-
cian. An evaluation higher than 80% was classified as
"adherent", whereas lower than 80% was considered asBMC Infectious Diseases 2004, 4:46 http://www.biomedcentral.com/1471-2334/4/46
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"non-adherent". The following adverse effects were con-
sidered: anaemia (haemoglobin <9.0 gr/dl), digestive
intolerance, dyslipidemia (serum cholesterol >240 mg/dl
and/or triglycerides >200 mg/dl), hepatitis, hyperglycae-
mia (glucose >150 mg/dl), lipodystrophy, pancreatitis,
peripheral neuropathy, rash, renal colic and thrombocy-
topenia (platelets <50,000 cells/mm3).
Three outcomes were considered for the study: 1. Immu-
nological success (IS): defined as T lymphocytes CD4+
cell count >200/mm3 at the end of the follow-up; 2. Viro-
logical success (VS) defined as a HIV viral load undetecta-
ble (<50 copies/ml) at the end of the follow-up; 3. Viro-
immunological success (VIS) defined as either undetecta-
ble HIV viral load and T lymphocytes CD4+ cell count
>200/mm3 at the end of the follow-up.
Evaluation of comorbidity
In order to evaluate the significance of non HIV-related
comorbid conditions, we used a modified version of the
Charlson comorbidity index which excludes AIDS from
the diagnosis [22]. Cardiovascular, pulmonary, neurolog-
ical, endocrine, renal, hepatic, gastrointestinal, rheumato-
logic diseases, coagulation disorders and cancer were
considered as comorbid non HIV-related conditions.
Statistical analysis
Quantitative variables were tested for normal distribution
and compared by means of Student's two tailed t-test. Dif-
ferences in group proportions were assessed by use of the
χ2 test or, for small numbers, Fisher's exact test. Stepwise
logistic regression models were used for each factor to
adjust for the effects of confounding variables. Two tailed
tests of significance at the p < 0.05 level were used to
determine statistical significance. Statistical analysis was
performed using the software program Intercooled Stata
6.0 (Stata Corporation, Texas).
Results
Epidemiological and clinical features of older patients at 
the time of HIV diagnosis
The rate of HIV diagnosis in patients aged ≥ 50 years
admitted to our in- and out-patient care remained con-
stant (about 10%) over the study-period.
From a total of 1265 subjects with new HIV-positive test,
129 (10,1%) subjects aged ≥ 50 years were identified.
Nine of them were not further considered because of miss-
ing data. One hundred twenty older subjects were evalu-
ated. Data were available for 476 younger subjects.
Table 1: Demographic and clinical characteristics of older (≥ 50 years) and younger (20–35 years) HIV-positive subjects in the period 
1997–2003.
Older n = 120 (%) Younger n = 476 (%) p
Male sex 91(76) 285 (60) <0.01
Age (mean ± SD), years 58 ± 5.1 31 ± 3.2 <0.01
Risk factor of HIV infection
Heterosexual 62(52) 199(42) 0.1
No risk reported 32(27) 119 (25) 0.6
Homosexual 19(16) 57 (12) 0.2
Injection drug users 6(5) 104(22) <0.01
Months between first HIV+ test and AIDS (mean ± SD) 1.8 ± 7.8 3.3 ± 6.7 0.4
Stage C of HIV infection* 62 (52) 114 (24) <0.01
PCP 9 (8) 14 (3) 0.02
HIV encephalopathy 9 (8) 9 (2) <0.01
Kaposi 8 (7) 5 (1) <0.01
Candidiasis 8 (7) 43 (9) 0.5
Cryptococcosis 5 (4) 1 (0.3) <0.01
Mycobacteriosis 4 (3) 5 (1) 0.2
Cryptosporidiosis 4 (3) 5 (1) 0.06
Tuberculosis 4 (3) 14 (3) 0.7
Isosporiasis 1 (1) 0 0.2
Bacterial pneumonia 1 (1) 0 0.2
Wasting syndrome 1 (1) 9 (2) 0.5
Toxoplasmosis 0 9 (2) 0.1
Cytomegalovirus retinitis 0 1 (0.3) 0.6
Lymphoma 7 (6) 9 (2) 0.05
CD4+ T cell/mm3 (mean ± SD)** 59.1 ± 65.3 105.3 ± 127.4 0.04
Deaths 16 (13) 14 (3) <0.01
*see Ref. n° 21; **at AIDS diagnosis;BMC Infectious Diseases 2004, 4:46 http://www.biomedcentral.com/1471-2334/4/46
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Among older subjects there were more males, less intrave-
nous drug abusers, more advanced HIV disease, more fre-
quent C stage of HIV infection and higher mortality,
(Table 1).
The reasons for the first HIV test were comparable both for
older and younger subjects. In particular, 30 (25%) older
subjects were asymptomatic. For those who were sympto-
matic, the more frequently observed symptoms were:
fever (25%), haematological dysfunctions (17%), weight
loss (14%), neurological (8%), gastrointestinal (6%) or
hepatic (7%) disorders.
Regarding AIDS-defining conditions, a significantly
higher frequency of PCP, HIV-encephalopathy, Kaposi's
sarcoma and cryptococcosis was observed in older HIV-
infected patients than in younger.
Matched case-control study
Thirty nine out of 120 HIV-positive older subjects were
not further considered: 29 because the duration of follow-
up was below six months and ten because the case-control
matching was not possible. A final number of 81 older
patients under regular HAART and with a follow-up of at
least six months (cases) were thus compared with 162
younger subjects (controls).
Baseline characteristics and evolution
Cases had a median age of 56.9 ± 5.2 years and controls
of 31.3 ± 3.2 years. As a result of the matching, 73% of
subjects in both groups were males and 49% were in CDC
stage C of HIV infection. HIV infection risk factors were
similar in the two groups, but eighteen (22%) cases
referred an unknown risk factor compared to 26 (16%)
controls (p = 0.1). The mean of CD4+ T cells was signifi-
cantly lower in cases compared to controls (107 ± 109
cell/mm3 vs. 178 ± 189 cell/mm3; p < 0.01), such as the
mean CD4 percentage (9% vs. 14%; p < 0.01). The mean
of CD8+ T cells at baseline was similar in cases and con-
trols (757 ± 380 cell/mm3 vs. 818 ± 362) (p = ns). Mean
of HIV viral load log was similar in the two groups (4.65
± 0.57 vs. 4.74 ± 0.76 copies/ml; p = ns). No statistical sig-
nificant difference was observed for haematological
parameters, serological markers of previous viral hepatitis
(type B or C) and syphilis. Laboratory tests only indicated
a significant increase of glycaemia in older patients (103.3
± 18.7 vs. 89.0 ± 10.6 mg/dl; p < 0.01).
Follow-up was similar in the two groups (40 ± 13 vs. 42 ±
11 months; p = ns), ranging from 6 to 78 months.
No differences were observed between cases and controls
in the number of hospitalisations (1.2 ± 2.1 vs. 1.3 ± 2.8;
p = ns).
Seven (9%) and six (4%) patients died in the case and
control groups, respectively (p = ns). All causes of death in
both groups were HIV-related conditions with the excep-
tion of one case who died for an acute mesenteric vascular
episode.
Table 2: Antiretroviral therapy in 81 cases and 162 controls
Cases n (%) Controls n (%) p
First line therapy 81 (100) 162 (100)
Combinations
-NRTI+PI 67 (83) 138 (85) 0.7
-NRTI+NNRTI 14 (17) 26 (16) 0.7
Duration; months (mean ± SD) 13.46 ± 10.23 16.67 ± 8.45 0.06
N° of patients who suspended 53 (66) 91 (56) 0.2
Cause of suspension
-side effects 30 (56) 37 (41) 0.1
-viro-immunological failure 8 (15) 15 (17) 0.6
Second line therapy 45 (56) 91 (56) 1
Third line therapy 11 (14) 31 (19) 0.4
Total number of drug changes (mean ± SD) 2.1 ± 0.9 2.0 ± 0.6 0.8,
Adherent to the last drug regimen 68 (84) 118 (73) 0.08
Side effects to HAART
dyslipidemia 32 (40) 55 (34) 0.5
digestive intolerance 26 (32) 58 (36) 0.6
lipodystrophy 12 (15) 23 (14) 0.7
hyperglycaemia 8 (10) 3 (2) 0.01
anaemia 8 (10) 3 (2) 0.01BMC Infectious Diseases 2004, 4:46 http://www.biomedcentral.com/1471-2334/4/46
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Comorbid conditions
Cases had more comorbid conditions than controls
(45.6% vs. 15.9%; p < 0.01). One third of the cases suf-
fered from cardiovascular diseases, a rare condition
among controls (32.2% vs. 2.1%; p < 0.01). Gastrointesti-
nal disorders (9.4% vs. 1.2%; p = 0.04) and diabetes
(11.0% vs. 2.1%; p = 0.02) were also significantly more
frequent among cases than controls. No statistically signif-
icant differences were found for cancer, pulmonary, renal
or endocrine diseases, chronic hepatitis and coagulation
disorders. The total comorbid points were 37 for cases and
20 for controls. Cases had also a higher mean Charlson
index in respect to controls (0.57 ± 0.92 vs. 0.12 ± 0.44; p
< 0.01).
Antiretroviral therapy
No statistically significant difference between cases and
controls was observed in type, number and duration of
HAART regimens. The first line antiretroviral therapy
included PI in more than 80% of cases and controls
(Table 2). The patients who required a change in antiret-
roviral therapy (second line therapy) received a therapeu-
tical cocktail including PI in 40% vs. 48% (p = ns) and
NNRTI in 57% vs. 50% (p = ns) of cases and controls,
respectively. Similar percentages were observed in the
patients who required another change of antiretroviral
therapy (third line therapy) during the follow-up. In the
first line drug regimen, side effects were more frequently
responsible of the change of the drug regimen in cases
compared with controls, although not reaching a statisti-
cally significant level (p = 0.1). A high level of adherence
to HAART was observed in both groups (82% vs. 75%; p
= ns). The more frequent adverse reactions were dyslipi-
demia, digestive intolerance and lipodystrophy in both
groups (p = ns). A significantly higher frequency of hyper-
glycaemia and anaemia was observed in cases than in con-
trols (Table 2).
Immunological and virological response
HAART related immunoreconstitution
Comparing the mean values obtained at baseline in both
cases and controls with those obtained at the end of the
follow-up, a statistically significant increase in T CD4+
cell number was observed. In particular, T CD4+ cell
count increased in 48 months from 107 ± 109 to 476 ±
258 for cases (p = 0.04), and from 178 ± 189 to 584 ± 252
for controls (p < 0.01). There was always a progressive lin-
ear enhancement in both groups at any individual time of
the follow-up. The lower values observed in cases in
respect to controls at baseline, persisted until the end of
the follow-up (Figure 1).
The increasing value of T CD4+ cell count every six
months in respect to baseline was comparable in the two
groups (Figure 2).
According to the above mentioned outcome definition, IS
was observed in 59 (73%) of the cases and 128 (79%) of
the controls (p = ns). The following variables were signif-
icantly associated with IS at univariate analysis: CDC stage
A (p = 0.01), low Charlson index (p = 0.01), CD4+ T cell
count at the beginning and at 6,12,18,24,30,36 months of
HAART (p < 0.01), months to achieve CD4+ T cell >200/
mm3 (p < 0.01), enhancement of CD4+ T cell count in the
first six months (p < 0.01), HIV viremia at 30 months (p
< 0.01).
HAART related viral suppression
A statistically significant reduction of HIV viral load was
observed in both cases and controls when comparing
baseline with the end of the follow-up values. In particu-
lar, means of HIV-RNA viral load log decreased in 48
months from 4.74 ± 0.57 to 2.01 ± 0.4 copies/ml in cases
(p < 0.01) and from 4.69 ± 0.76 to 1.6 ± 0.2 copies/ml in
controls (p < 0.01).
HIV viral load reduced under antiretroviral therapy in
both groups in a comparable manner. In fact, there was no
statistically significant difference between cases and con-
trols at any individual time of the follow-up (Figure 3).
According to the above mentioned outcome definition,
VS was observed in 66 (82%) of cases and 121 (75%) of
controls (p = ns). The following variables were signifi-
cantly associated with VS at univariate analysis: CDC stage
A (p = 0.02), high adherence to HAART (p = 0.01),
dyslipidemia as adverse effect of HAART (p = 0.01), HIV
viral load at 6 (p < 0.01) and 24 months (p = 0.02).
HAART related virological and immunological outcome
According to our definition of the outcome, VIS was
observed in 53 (66%) of cases and 100 (62%) of controls
(p = ns). The following variables were significantly associ-
ated with VIS at univariate analysis: CDC stage A (p <
0.01), high adherence to HAART (p = 0.02), dyslipidemia
as adverse effect of HAART (p < 0.01), CD4+ T cell
number at baseline and at 6,12,18,24,30,36 months of
HAART (p < 0.01), enhancement of CD4+ T cellcount in
the first six months (p < 0.01), HIV viral load at 6 (p =
0.04) and 30 months (p = 0.01).
No statistical difference in immuno-virological response
was found between cases and controls when, as cases,
only a subgroup of patients aged > 60 years was consid-
ered (data not shown).
Multivariate analysis
In a multivariate logistic regression model, after adjust-
ment for sex and Charlson index, there was no statistically
significant difference between cases and controls for IS, VS
and VIS (p = ns). Similar results were obtained when CDCBMC Infectious Diseases 2004, 4:46 http://www.biomedcentral.com/1471-2334/4/46
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stage A and CD4+ T cell count at HIV diagnosis were
added to the model.
Another model including sex, Charlson index, CDC stage
A, CD4+ T cell count at the beginning of HAART, adher-
ence and dyslipidemia as adverse effect of HAART did not
show any statistically significant difference between cases
and controls for IS, VS and VIS.
Further adjustment for sex, Charlson index, CDC stage A,
adherence, dyslipidemia as adverse effect of HAART,
CD4+ T cell count at beginning of HAART and after six
months of therapy, enhancement of CD4+ T cell count in
the first six months, months to achieve CD4 + T cell count
>200/mm3, HIV viral load at six months did not modify
the results.
Discussion
This study, conducted in an Italian population, shows that
in the HAART era, the percentage of older patients out of
the new HIV infections is approximately 10%, slightly
higher than previously reported [23]. The impact of long
term HAART-related immunoreconstitution in this sub-
population of HIV patients could reduce the incidence of
older patients with AIDS within the next years to less than
the 12% recently reported [1].
The first part of our study confirms previous pre-HAART
era observations, about more severe HIV infection in
older subjects [2-10]. In fact, higher frequency of patients
with AIDS at HIV diagnosis, lower T CD4+ cell count and
higher mortality in older subjects in respect of younger
were observed. A late diagnosis or a more aggressive
T CD4+ cell count/mm3 (mean ± SD) at the beginning of HAART and each six months of follow-up in cases and controls Figure 1
T CD4+ cell count/mm3 (mean ± SD) at the beginning of HAART and each six months of follow-up in cases and controls.
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impact of HIV infection in older population could explain
these results. The first possibility could reflect low level
information and/or physicians' insufficient suspicion
[2,24], despite the world-wide durable informative cam-
paigns and preventive efforts on this issue. Alternatively, a
shorter or less symptomatic pre-AIDS phase, as already
reported in older HIV-positive subjects, could contribute
to the late diagnosis [2]. On the other hand, the more
aggressive impact of HIV infection in older population
has been related to the hypothesis that HIV is an addi-
tional aggravating factor to an already debilitated host
potentially presenting numerous comorbidities, less phys-
iological reserves [10,14] and a less responsive immune
system [2,25]. In fact, in HIV-negative older subjects,
important changes in cellular and humoral components
of the immune system including defects in T CD4+ lym-
phocyte function, have been described [26].
Regarding HIV-risk behaviour, our data indicate the heter-
osexual route as the most frequent in older patients, fol-
lowed by no risk reported, homosexual contacts,
intravenous drug abuse. In particular, our data confirm
recent reports [8,27] indicating an increased incidence of
HIV subjects with no risk reported. This aspect could con-
tribute to the above mentioned low level of suspicion of
HIV diagnosis in older subjects. It is of interest that a large
T CD4+ cell count/mmc six month increment (mean ± SD) from the beginning of HAART to the end of the follow-up in cases  and controls Figure 2
T CD4+ cell count/mmc six month increment (mean ± SD) from the beginning of HAART to the end of the follow-up in cases 
and controls
0
50
100
150
200
250
300
350
400
450
6 1 21 82 43 03 64 24 85 46 06 67 2
I
n
c
r
e
m
e
n
t
 
o
f
 
T
 
C
D
4
+
 
c
e
l
l
s
 
f
r
o
m
 
b
a
s
e
l
i
n
e
cases
controls
76      73      67     60      55      51      51     48     47      46      45      43
154    150    139   127    116   106    103     101    99      97      95      92
months
cases
controls  
111±76
155±89
208±123
245±116
261±144
303±125
342±169
374±151
405±197
420±203
420±203420±203
144±87
162±78
219±95
241±105
292±113
319±118
321±107 326±134
394±206
416±198
416±198
416±198BMC Infectious Diseases 2004, 4:46 http://www.biomedcentral.com/1471-2334/4/46
Page 8 of 11
(page number not for citation purposes)
epidemiological survey in the US general population has
reported a prevalence of at least one risk factor for HIV
infection in about 10% of subjects aged 50 years or older
[28].
To date, no studies have indicated that older AIDS
patients should be treated differently for HIV disease.
Clinical drug trials often exclude older patients because of
multiple medical problems, comorbidities or co-existing
non HIV-related medication regimens [29]. The first avail-
able literature data obtained in a large population of HIV-
positive patients treated with zidovudine in the early
nineties showed that age was an independent predictor of
rapid progression to AIDS and shorter survival [30]. On
the contrary, antiretroviral therapy was the only inde-
pendent predictor of survival after the diagnosis of AIDS
in older HIV-positive subjects in the pre HAART era [31].
Very little literature and study has been devoted specifi-
cally to the role of protease inhibitors and aggressive
antiretroviral triple therapy in elderly patients. Few data
have been published concerning the specific response of
older patients to new HIV antiretroviral treatments, and
currently there are no guidelines for specific antiretroviral
treatment modalities for patients>50 years of age. How-
ever, a poor immunological response under HAART was
observed in small groups of patients [15,16] possibly due
to the well known depressed thymic function of the elder-
lies [15-17]. Only few reports showed a similar virological
Comparison of HIV-RNA log 10 (mean ± SD) between cases and controls from baseline to the end of follow-up Figure 3
Comparison of HIV-RNA log 10 (mean ± SD) between cases and controls from baseline to the end of follow-up.
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and immunological outcome in older HIV-positive com-
pared with younger subjects [18,19].
This six year prospective matched case control study not
only confirms this observation but indicates that older
patients under HAART experienced a successful immuno-
logical response comparable to younger subjects also in a
long term follow-up, in line with preliminary reports [32-
34]. In fact, our older patients, starting HAART with a
lower level of T CD4+ cells than younger, obtained a sig-
nificant increment in their T CD4+ cell count, with the
same rapidity, intensity and persistence in time as
observed in younger patients.
Meticulous adherence to HAART is necessary to achieve an
optimal clinical and virological response. A variety of fac-
tors may predict medication adherence among HIV-
infected adults. Although older age is usually associated
with higher rates of antiretroviral adherence, older partic-
ipants who were cognitively impaired could have diffi-
culty in adequately adhering to their medication regimen
[35-37]. Our findings indicate that this goal could be
achieved independently from age. In fact, although
thymic functions decline with age, substantial output of T
CD4+ cells can be maintained into late adulthood, thus
contributing to HAART-related immune recovery in older
HIV-positive patients [38-40].
Early work also demonstrated a positive association
between age and the plasma HIV-1-RNA copy number at
the time of identification of HIV-1 serostatus among
recently diagnosed older HIV-1 positive individuals [41].
However, this could have been caused by a lead-time diag-
nostic bias, with a greater delay among older individuals.
No differences were observed in virological response as
indicated by viral load reduction in older patients with
respect to younger. This result is in line with previous
reports [15,18] including a large study which indicated
that older age decreases the risk to have viral load greater
than 1000 copies/ml in HIV-positive subjects under
HAART [2]. In a recent report, older age was associated
with lower levels of HIV-1 replication, independent of
antiretroviral therapy usage, regimen adherence, and dis-
eases stage. It is suggested that the effect may be caused by
changes in viral evolution or immunological monitoring
specific to older individuals with HIV-1 infection [42].
In our study both the frequency and the distribution of
adverse effects of HAART were similar between the two
groups, with the exception of anaemia and hyperglycae-
mia which were more frequent in older patients. Hyperg-
lycaemia can be explained because diabetes is a frequent
comorbid condition among older. Older subjects were
more susceptible than younger to adverse effects in the
first line therapy; consequently they had to change ther-
apy more frequently.
Univariate analysis showed an association of low Charl-
son index with immunological success. However, consid-
ering that the Charlson index was higher in older patients,
none of the models of multivariate analysis indicated an
association between comorbidity and virological and/or
immunological response. Nonetheless previous studies
have suggested a more rapid course and a decreased sur-
vival in older HIV-positive patients because of the pres-
ence of comorbidities [10], our data did not confirm this
association (data not shown). Interestingly, cardiovascu-
lar disease and diabetes were the more frequent comor-
bidities in our older population.
Dyslipidemia and lipodystrophy in association with gas-
trointestinal disorders were the more frequent adverse
reactions. In view of these results, of the recent reports of
endothelial vascular damage, premature atherosclerosis
and coronary events in younger HAART-treated patients
[43-45], an important increase of cardiovascular event
incidence in older HIV-positive patients under HAART
could not be excluded to occur in the forthcoming years.
Conclusions
In conclusion, we strongly underline the need for an early
diagnosis of HIV infection in older subjects through
implementation of educational campaigns specifically
targeted to this population. In relation to older people,
physicians should consider more often the possibility of
HIV diagnosis, through more screening and counselling.
An early diagnosis is mandatory because, although older
subjects present with more severe HIV infection, the use of
HAART allow them to achieve the same viro-immunolog-
ical response as younger individuals. At present, there is
an increasing number of older subjects living with HIV
either because of new HIV diagnosis in older population
or because who have previously acquired HIV infection
now become older due to HAART improved survival. It is
reasonable to predict that the average age of chronically
treated HIV-positive patients will progressively increase in
the forthcoming years. Based on this reality, ageing with
HIV is a newly manifested chronic disease with a complex
long-term management in consideration also of the
impact of HIV and HAART on the natural history of other
chronic diseases typically associated with older age.
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